Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Seattle Genetics Inc. (SGEN), Cerus Corporation (CERS): Baker Bros. Advisors’ Latest Moves

Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday. The firm continued to boost its exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) by approximately 3.6%, to 25.2 million shares of common stock, and trimmed its stake in Cerus Corporation (NASDAQ:CERS) by 1.8%, to 11.7 million shares of common stock. These stakes represent 20.3% and 15.0% of the companies’ shares outstanding, respectively.

Baker Bros. Advisors is a New York City-based hedge fund founded in the year 2000. The firm typically invests in the healthcare segment, which comprises 99.8% of its third quarter equity portfolio, worth about $7.9 billion.

Felix Baker - Baker Bros.

Seattle Genetics, Inc. (NASDAQ:SGEN) is a $4.23 billion market cap biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The Baker brothers have been augmenting their wage on this company for a while now. Since the end of the third quarter, the fund already increased its exposure once. On this second occasion, it took its stake to 25.22 million shares, as the company’s pipeline continues to develop. The purchases were made for prices ranging from $32.56 per share to $34.95 per share.

Other major institutional investors betting on Seattle Genetics, Inc. (NASDAQ:SGEN) are Peter Kolchinsky’s RA Capital Management and Pasco Alfaro and Richard Tumure’s Miura Global Management. Both these funds started new positions in the company over the third quarter, with 5.38 million shares and 4.16 million shares, respectively.

Cerus Corporation (NASDAQ:CERS) is a biomedical products company with a market cap of $363.1 million. It focuses on commercializing the INTERCEPT Blood System to enhance blood safety. As the stock price escalated over the past few days, Baker Bros. Advisors decided to sell some of its stock, reducing its stake to a 15.0% of the company. With such a large involvement in the company, one should not interpret this one as a bearish move, but rather as a chance of making some money out of their investment. In fact, despite this reduction, the fund continues to stand as the largest institutional investor, amongst those we track.

Also betting big on Cerus Corporation (NASDAQ:CERS) are Samuel Isaly and Chuck Royce. Both of them upped their stakes over the third quarter, by 70% and 2%, respectively, and now own 7.18 million shares and 3.76 million shares, correspondingly.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!